Prozone Effect in the Diagnosis of Lupus Anticoagulant for the Lupus Anticoagulant-Hypoprothrombinemia Syndrome.

OBJECTIVES The main clinical sequela of a lupus anticoagulant is increased thrombosis risk. However, bleeding due to lupus anticoagulant-hypoprothrombinemia syndrome is a rare but well-described manifestation of antiphospholipid syndrome. The association of acute acquired hypoprothrombinemia is caused by a lupus anticoagulant's specificity to prothrombin, which results in clearance of prothrombin and bleeding due to hypoprothrombinemia (usually <10% of normal). Severe life-threatening bleeding is most frequently reported in children with systemic lupus erythematosus or in healthy children after viral infection. In such cases, steroid therapy is usually effective in controlling the bleeding problems and improving prothrombin levels. METHODS We report one pediatric patient with a lupus anticoagulant who had acute hemorrhagic diathesis. RESULTS The diagnosis in this case was complicated by the presence of a prozone effect in lupus anticoagulant testing. The prozone effect (also known as hook effect) refers to situations where very high concentrations of antibody mask detection, typically in antigen-antibody reactions, which depend on visualization of agglutination. Decreasing the antibody/antigen ratio results in detectable antigen-antibody complexes. CONCLUSIONS We report for the first time a variation on this theme in a patient with a lupus anticoagulant-type antiphospholipid antibody and hypoprothrombinemia, which corrected with immunosuppression and restoration of normal prothrombin levels.

[1]  Ji Soo Kim,et al.  Pulmonary hemorrhage in pediatric lupus anticoagulant hypoprothrombinemia syndrome , 2014, Korean journal of pediatrics.

[2]  L. Lingappa,et al.  Variable Manifestations of Severe Hypoprothrombinemia (Factor II Deficiency): 2 Cases , 2014 .

[3]  A. Tripodi,et al.  More on: laboratory investigation of lupus anticoagulants: mixing studies are sometimes required , 2011, Journal of thrombosis and haemostasis : JTH.

[4]  G. Kershaw,et al.  Laboratory investigation of lupus anticoagulants: mixing studies are sometimes required , 2010, Journal of thrombosis and haemostasis : JTH.

[5]  V. Baca,et al.  Diagnosis of lupus anticoagulant in the lupus anticoagulant‐hypoprothrombinemia syndrome: Report of two cases and review of the literature , 2002, American journal of hematology.

[6]  M. Lockshin,et al.  Lupus anticoagulant–hypoprothrombinemia syndrome associated with systemic lupus erythematosus: report of 2 cases and review of literature , 1999, Lupus.

[7]  G. Finazzi,et al.  Severe bleeding due to acquired hypoprothrombinemia-lupus anticoagulant syndrome. Case report and review of literature. , 1997, Haematologica.

[8]  Joan Hadzi-Nesic,et al.  Transient hemorrhagic diathesis associated with an inhibitor of prothrombin with lupus anticoagulant in a 1½‐year‐old girl: Report of a case and review of the literature , 1996, American journal of hematology.

[9]  E. Silverman,et al.  Hypoprothrombinemia in childhood systemic lupus erythematosus. , 1994, Seminars in arthritis and rheumatism.

[10]  D. Triplett,et al.  A Hexagonal (II) Phase Phospholipid Neutralization Assay for Lupus Anticoagulant Identification , 1993, Thrombosis and Haemostasis.

[11]  T. Barbui,et al.  Lupus Anticoagulant IgG's (LA) Are Not Directed to Phospholipids only, but to a Complex of Lipid-Bound Human Prothrombin , 1991, Thrombosis and Haemostasis.

[12]  R. Hift,et al.  Acquired hypoprothrombinaemia and lupus anticoagulant: response to steroid therapy. , 1991, British journal of rheumatology.

[13]  A. Janoff,et al.  Distinguishing Plasma Lupus Anticoagulants from Anti-Factor Antibodies Using Hexagonal (II) Phase Phospholipids , 1989, Thrombosis and Haemostasis.

[14]  P. Cullis,et al.  Human hybridoma lupus anticoagulants distinguish between lamellar and hexagonal phase lipid systems. , 1986, The Journal of biological chemistry.

[15]  Y. Et,et al.  Purification and kinetic studies on a circulating anticoagulant in a suspected case of lupus erythematosus. , 1965 .

[16]  L. Gaston,et al.  Purification and Kinetic Studies on a Circulating Anticoagulant in a Suspected Case of Lupus Erythematosus* , 1965, Thrombosis and Haemostasis.

[17]  A. Loeliger,et al.  Prothrombin as Co-Factor of the Circulating Anticoagulant in Systemic Lupus Erythematosus? , 1959, Thrombosis and Haemostasis.